Health Care Archives - Page 417 of 478

1 minute read

Bristol Myers’ Deucravacitinib Scores FDA Approval For Plaque Psoriasis

September 12, 6:00 AM

The FDA approved Bristol Myers Squibb Co’s (NYSE:BMY) Sotyktu (deucravacitinib), an allosteric tyrosine kinase 2 (TYK2) inhibitor, for moderate-to-severe plaque psoriasis…

AMGN

1 minute read

Bill Gates Says He Loves Learning About This Topic And Shares ‘Cool Research’ Being Conducted

By Shanthi Rexaline

September 10, 5:18 PM

Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates recently took to Twitter to share an article published in the Harvard M

MSFT

3 minute read

Important Biotech Catalysts For September 9, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

September 9, 5:47 PM

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ:SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to…

ADAP

1 minute read

Spectrum Gets FDA Nod For Febrile Neutropenia Candidate, Sees Commercial Launch In Q4 2022

By Ragothaman Srinivasan

September 9, 4:57 PM

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ (NASDAQ: SPPI) lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.

SPPI

1 minute read

With New Growth Avenues, Analysts Boost Price Targets For This Botox Competitor

By Vandana Singh

September 9, 3:10 PM

A major overhang has been lifted with the FDA approval of Revance Therapeutics Inc’s (NASDAQ:RVNC) Daxxify (DaxibotulinumtoxinA-lanm). The catalyst also provides a…

RVNC

1 minute read

Citing ‘Lightning Fast Growth,’ Needham Upgrades This Vascular Device Company

By Vandana Singh

September 9, 2:21 PM

Needham upgraded Penumbra Inc (NYSE:PEN) to Buy from Hold, with a price target of $244. The analyst notes that management indicated…

PEN

1 minute read

Immunocore Shares Fall After Early Solid Cancer Trial Data Of TCR Therapy

By Vandana Singh

September 9, 1:11 PM

Immunocore Holdings plc (NASDAQ:IMCR) released initial Phase 1 data for the first off-the-shelf ImmTAC targeting PRAME, demonstrating that IMC-F106C is well…

IMCR

1 minute read

AstraZeneca-Merck’s Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer

By Vandana Singh

September 9, 12:40 PM

AstraZeneca plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK) announced long-term follow-up results from the Phase 3 PAOLA-1 and SOLO-1 trials in first-line…

AZN

1 minute read

There’s ‘Outsized’ Risk-Reward For This Biotech, Morgan Stanley Says, Predicting Shares Could Grow More Than 30%

By Vandana Singh

September 9, 11:22 AM

Morgan Stanley has assumed coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with an Overweight (previously Underweight) rating and a price target of $57 from…

IONS

1 minute read

‘Highly Compelling’ Eye Drug Data Has Wall Street Stampeding To Buy This ‘Large Cap Growth Story.’ Even After $15B In Market Cap Was Added

By Vandana Singh

September 9, 11:14 AM

Morgan Stanley upgraded Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) to Overweight from Equal Weight with a price target of $851, up from $625. The analyst…

REGN